{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T13:48:10Z","timestamp":1649166490895},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,5,3]],"date-time":"2018-05-03T00:00:00Z","timestamp":1525305600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s00108-018-0434-1","type":"journal-article","created":{"date-parts":[[2018,5,3]],"date-time":"2018-05-03T05:04:16Z","timestamp":1525323856000},"page":"536-543","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Autoimmunhepatitis \u2013 Standard- und Zweitlinientherapie"],"prefix":"10.1007","volume":"59","author":[{"given":"R.","family":"Taubert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Jaeckel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,3]]},"reference":[{"key":"434_CR1","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","volume":"31","author":"F Alvarez","year":"1999","unstructured":"Alvarez F, Berg PA, Bianchi FB et\u00a0al (1999) International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J\u00a0Hepatol 31:929\u2013938","journal-title":"J Hepatol"},{"issue":"1","key":"434_CR2","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/hep.28517","volume":"64","author":"YY Chen","year":"2016","unstructured":"Chen YY, Jeffery HC, Hunter S et al (2016) Human intrahepatic tregs are functional, require IL-2 from effector cells for survival and are susceptible to fas ligand mediated apoptosis. Hepatology 64(1):138\u2013150. \n                    https:\/\/doi.org\/10.1002\/hep.28517","journal-title":"Hepatology"},{"key":"434_CR3","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/S0168-8278(05)80279-X","volume":"18","author":"AJ Czaja","year":"1993","unstructured":"Czaja AJ, Carpenter HA, Santrach PJ et\u00a0al (1993) Evidence against hepatitis viruses as important causes of severe autoimmune hepatitis in the United States. J\u00a0Hepatol 18:342\u2013352","journal-title":"J Hepatol"},{"key":"434_CR4","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1053\/j.gastro.2014.04.022","volume":"147","author":"YS Boer De","year":"2014","unstructured":"De Boer YS, Van Gerven NM, Zwiers A et al (2014) Genome-wide association study identifies variants associated with autoimmune hepatitis type 1. Gastroenterology 147:443\u2013452.e5","journal-title":"Gastroenterology"},{"key":"434_CR5","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1097\/MEG.0000000000001019","volume":"30","author":"M Lemos-Bonotto De","year":"2018","unstructured":"De Lemos-Bonotto M, Valle-Tovo C, Costabeber AM et al (2018) A systematic review and meta-analysis of second-line immunosuppressants for autoimmune hepatitis treatment. Eur J Gastroenterol Hepatol 30:212\u2013216","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"434_CR6","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1055\/s-0043-120199","volume":"55","author":"Deutsche Gesellschaft f\u00fcr Gastroenterologie, Verdauungs- und Stoffwechselkrankheite","year":"2017","unstructured":"Deutsche Gesellschaft f\u00fcr Gastroenterologie, Verdauungs- und Stoffwechselkrankheite, Deutsche Gesellschaft f\u00fcr Innere Medizin, Deutsche M. Crohn\/Colitis ulcerosa Vereinigung et al (2017) Practice guideline autoimmune liver diseases\u2014AWMF-Reg. No.\u00a0021-27. Z\u00a0Gastroenterol 55:1135\u20131226","journal-title":"Z Gastroenterol"},{"key":"434_CR7","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/ajg.2015.139","volume":"110","author":"HK Dhaliwal","year":"2015","unstructured":"Dhaliwal HK, Hoeroldt BS, Dube AK et al (2015) Long-term prognostic significance of persisting histological activity despite biochemical remission in autoimmune hepatitis. Am J Gastroenterol 110:993\u2013999","journal-title":"Am J Gastroenterol"},{"key":"434_CR8","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/s41598-017-18818-5","volume":"8","author":"J Diestelhorst","year":"2018","unstructured":"Diestelhorst J, Junge N, Jonigk D et al (2018) Baseline IL-2 and the AIH score can predict the response to standard therapy in paediatric autoimmune hepatitis. Sci Rep 8:419","journal-title":"Sci Rep"},{"key":"434_CR9","doi-asserted-by":"publisher","first-page":"e0181107","DOI":"10.1371\/journal.pone.0181107","volume":"12","author":"J Diestelhorst","year":"2017","unstructured":"Diestelhorst J, Junge N, Schlue J et al (2017) Pediatric autoimmune hepatitis shows a\u00a0disproportionate decline of regulatory T cells in the liver and of IL-2 in the blood of patients undergoing therapy. PLoS ONE 12:e181107","journal-title":"PLoS ONE"},{"key":"434_CR10","volume-title":"Leitlinie Osteoporose","author":"DVO","year":"2014","unstructured":"DVO (2014) Leitlinie Osteoporose"},{"key":"434_CR11","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1016\/j.cgh.2017.06.001","volume":"15","author":"C Efe","year":"2017","unstructured":"Efe C, Hagstrom H, Ytting H et al (2017) Efficacy and safety of mycophenolate mofetil and tacrolimus as second-line therapy for patients with autoimmune hepatitis. Clin Gastroenterol Hepatol 15:1950\u20131956","journal-title":"Clin Gastroenterol Hepatol"},{"key":"434_CR12","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","volume":"63","author":"European Association for the Study of the L iver","year":"2015","unstructured":"European Association for the Study of the L iver (2015) EASL clinical practice guidelines: autoimmune hepatitis. J\u00a0Hepatol 63:971\u20131004","journal-title":"J Hepatol"},{"key":"434_CR13","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.jhep.2013.10.020","volume":"60","author":"L Gronbaek","year":"2014","unstructured":"Gronbaek L, Vilstrup H, Jepsen P (2014) Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study. J\u00a0Hepatol 60:612\u2013617","journal-title":"J Hepatol"},{"key":"434_CR14","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.jhep.2016.05.023","volume":"65","author":"J Hartl","year":"2016","unstructured":"Hartl J, Denzer U, Ehlken H et\u00a0al (2016) Transient elastography in autoimmune hepatitis: timing determines the impact of inflammation and fibrosis. J\u00a0Hepatol 65:769\u2013775","journal-title":"J Hepatol"},{"key":"434_CR15","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/hep.22322","volume":"48","author":"EM Hennes","year":"2008","unstructured":"Hennes EM, Zeniya M, Czaja AJ et\u00a0al (2008) Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 48:169\u2013176","journal-title":"Hepatology"},{"key":"434_CR16","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJM199510123331502","volume":"333","author":"PJ Johnson","year":"1995","unstructured":"Johnson PJ, Mcfarlane IG, Williams R (1995) Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N\u00a0Engl J Med 333:958\u2013963","journal-title":"N Engl J Med"},{"key":"434_CR17","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1136\/gut.21.1.78","volume":"21","author":"AP Kirk","year":"1980","unstructured":"Kirk AP, Jain S, Pocock S et\u00a0al (1980) Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis. Gut 21:78\u201383","journal-title":"Gut"},{"key":"434_CR18","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1002\/hep.23584","volume":"51","author":"MP Manns","year":"2010","unstructured":"Manns MP, Czaja AJ, Gorham JD et\u00a0al (2010) Diagnosis and management of autoimmune hepatitis. Hepatology 51:2193\u20132213","journal-title":"Hepatology"},{"key":"434_CR19","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1053\/j.gastro.2010.06.046","volume":"139","author":"MP Manns","year":"2010","unstructured":"Manns MP, Woynarowski M, Kreisel W et\u00a0al (2010) Budesonide induces remission more effectively than prednisone in a\u00a0controlled trial of patients with autoimmune hepatitis. Gastroenterology 139:1198\u20131206","journal-title":"Gastroenterology"},{"key":"434_CR20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jaut.2016.02.007","volume":"69","author":"P Muller","year":"2016","unstructured":"Muller P, Messmer M, Bayer M et al (2016) Non-alcoholic fatty liver disease (NAFLD) potentiates autoimmune hepatitis in the CYP2D6 mouse model. J\u00a0Autoimmun 69:51\u201358","journal-title":"J Autoimmun"},{"key":"434_CR21","first-page":"193","volume":"5","author":"S Nasseri-Moghaddam","year":"2013","unstructured":"Nasseri-Moghaddam S, Nikfam S, Karimian S et al (2013) Cyclosporine-A versus prednisolone for induction of remission in auto-immune hepatitis: interim analysis report of a\u00a0randomized controlled trial. Middle East J Dig Dis 5:193\u2013200","journal-title":"Middle East J Dig Dis"},{"issue":"2","key":"434_CR22","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.cgh.2016.12.040","volume":"16","author":"M Peiseler","year":"2017","unstructured":"Peiseler M, Liebscher T, Sebode M et al (2017) Efficacy and limitations of budesonide as a\u00a0second-line treatment for patients with autoimmune hepatitis. Clin Gastroenterol Hepatol 16(2):260\u2013267.e1. \n                    https:\/\/doi.org\/10.1016\/j.cgh.2016.12.040","journal-title":"Clin Gastroenterol Hepatol"},{"key":"434_CR23","volume-title":"Epidemiologisches Bulletin. 34","author":"RKI","year":"2017","unstructured":"RKI (2017) Epidemiologisches Bulletin. 34"},{"key":"434_CR24","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1055\/s-0037-1607453","volume":"37","author":"SK Roberts","year":"2017","unstructured":"Roberts SK, Kemp W (2017) Salvage therapies for autoimmune hepatitis: a critical review. Semin Liver Dis 37:343\u2013362","journal-title":"Semin Liver Dis"},{"key":"434_CR25","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/hep.1840080414","volume":"8","author":"AJ Stellon","year":"1988","unstructured":"Stellon AJ, Keating JJ, Johnson PJ et\u00a0al (1988) Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal. Hepatology 8:781\u2013784","journal-title":"Hepatology"},{"key":"434_CR26","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1136\/gut.16.11.876","volume":"16","author":"WH Summerskill","year":"1975","unstructured":"Summerskill WH, Korman MG, Ammon HV et\u00a0al (1975) Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut 16:876\u2013883","journal-title":"Gut"},{"key":"434_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s11377-018-0251-z","author":"R Taubert","year":"2018","unstructured":"Taubert R, Manns MP (2018) Autoimmunhepatitis. Gastroenterologe. \n                    https:\/\/doi.org\/10.1007\/s11377-018-0251-z","journal-title":"Gastroenterologe"},{"key":"434_CR28","doi-asserted-by":"publisher","first-page":"e0179074","DOI":"10.1371\/journal.pone.0179074","volume":"12","author":"R Taubert","year":"2017","unstructured":"Taubert R, Hardtke-Wolenski M, Noyan F et al (2017) Hyperferritinemia and hypergammaglobulinemia predict the treatment response to standard therapy in autoimmune hepatitis. PLoS ONE 12:e179074","journal-title":"PLoS ONE"},{"key":"434_CR29","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jhep.2012.09.009","volume":"58","author":"NM Gerven Van","year":"2013","unstructured":"Van Gerven NM, Verwer BJ, Witte BI et\u00a0al (2013) Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. J\u00a0Hepatol 58:141\u2013147","journal-title":"J Hepatol"},{"issue":"1","key":"434_CR30","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1146\/annurev-pathol-020117-043534","volume":"13","author":"GJ Webb","year":"2017","unstructured":"Webb GJ, Hirschfield GM, Krawitt EL et\u00a0al (2017) Cellular and molecular mechanisms of autoimmune hepatitis. Annu Rev Pathol 13(1):247\u2013292. \n                    https:\/\/doi.org\/10.1146\/annurev-pathol-020117-043534","journal-title":"Annu Rev Pathol"},{"key":"434_CR31","doi-asserted-by":"publisher","first-page":"e92267","DOI":"10.1371\/journal.pone.0092267","volume":"9","author":"WC Zhang","year":"2014","unstructured":"Zhang WC, Zhao FR, Chen J et al (2014) Meta-analysis: diagnostic accuracy of antinuclear antibodies, smooth muscle antibodies and antibodies to a\u00a0soluble liver antigen\/liver pancreas in autoimmune hepatitis. PLoS ONE 9:e92267","journal-title":"PLoS ONE"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-018-0434-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-018-0434-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-018-0434-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T19:17:22Z","timestamp":1556824642000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-018-0434-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,3]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["434"],"URL":"https:\/\/doi.org\/10.1007\/s00108-018-0434-1","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,3]]},"assertion":[{"value":"3 May 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"R.\u00a0Taubert erhielt Vortragshonorare von der Falk Foundation GmbH, MSD und AbbVie, Kongressreiseunterst\u00fctzung durch Astellas und einen von Astellas gesponserten Forschungspreis. E.\u00a0Jaeckel erhielt Vortragshonorare von der Falk Foundation GmbH und Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}